Spirepoint Private Client LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Spirepoint Private Client LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 56.8% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,907 shares of the biopharmaceutical company's stock after selling 28,822 shares during the period. Spirepoint Private Client LLC's holdings in Pfizer were worth $555,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Consolidated Portfolio Review Corp lifted its position in Pfizer by 22.9% during the first quarter. Consolidated Portfolio Review Corp now owns 147,854 shares of the biopharmaceutical company's stock valued at $3,747,000 after purchasing an additional 27,541 shares in the last quarter. Lazari Capital Management Inc. grew its stake in shares of Pfizer by 93.6% during the 1st quarter. Lazari Capital Management Inc. now owns 62,380 shares of the biopharmaceutical company's stock valued at $1,581,000 after acquiring an additional 30,151 shares during the period. Legacy Advisors LLC boosted its position in shares of Pfizer by 7.1% in the first quarter. Legacy Advisors LLC now owns 64,203 shares of the biopharmaceutical company's stock worth $1,627,000 after purchasing an additional 4,243 shares during the period. AssuredPartners Investment Advisors LLC lifted its stake in shares of Pfizer by 49.6% during the 1st quarter. AssuredPartners Investment Advisors LLC now owns 60,969 shares of the biopharmaceutical company's stock valued at $1,545,000 after buying an additional 20,210 shares in the last quarter. Finally, GHP Investment Advisors Inc. increased its stake in Pfizer by 12.6% in the 1st quarter. GHP Investment Advisors Inc. now owns 13,523 shares of the biopharmaceutical company's stock worth $343,000 after buying an additional 1,517 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Up 1.1%

NYSE:PFE traded up $0.28 during mid-day trading on Tuesday, hitting $24.31. 34,208,466 shares of the company's stock traded hands, compared to its average volume of 46,661,199. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $138.18 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a fifty day moving average of $23.30 and a 200 day moving average of $24.88. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.08%. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.